Flx Bio Inc., of South San Francisco, selected FLX-475 as its first immuno-oncology clinical candidate for the treatment of cancer. FLX-475 is described as an oral, small-molecule antagonist of CCR4, a receptor protein that plays a role in the recruitment and accumulation of regulatory T cells in the tumor environment. The company expects to enter the clinic with FLX-475 late this year.